



Figure S1 Kaplan-Meier survival curves of OS and PFS grouped by LDH for 614 patients in the whole cohort. (A) The OS curve of ESCC patients underwent chemoradiotherapy classified by LDH before matching; (B) The PFS curve of ESCC patients underwent chemoradiotherapy classified by LDH before matching; OS, overall survival; PFS, progression-free survival; LDH, lactate dehydrogenase.

Table S1 Univariate and multivariate analysis of PFS in patients with ESCC before propensity score matching

Variable	Univariate		Multivariate	
	HR (95% CI)	P value	HR (95% CI)	P value
Gender (female vs. male)	0.74 (0.58, 0.95)	0.019	0.77 (0.60, 0.99)	0.048
Age (>69 vs. ≤69 years)	1.27 (1.00, 1.61)	0.047	1.09 (0.84, 1.42)	0.515
ECOG PS (1–2 vs. 0)	1.34 (1.10, 1.64)	0.004	1.22 (0.97, 1.54)	0.086
cT stage (T3-4 vs. T1-2)	1.30 (0.90, 1.86)	0.159	–	–
cN stage (N+ vs. N0)	1.70 (1.22, 2.38)	0.002	1.54 (1.09, 2.16)	0.014
cM stage (M1 vs. M0)	1.70 (1.36, 2.12)	<0.001	1.49 (1.18, 1.89)	0.001
Differentiation (moderate/poor vs. high)	1.09 (0.85, 1.41)	0.496	–	–
Tumor length (>6.5 vs. ≤6.5 cm)	1.44 (1.13, 1.83)	0.003	1.40 (1.09, 1.79)	0.008
Tumor location				
Upper vs. cervical	0.89 (0.62, 1.29)	0.541	0.84 (0.58, 1.26)	0.348
Medium vs. cervical	1.22 (0.87, 1.72)	0.162	1.01 (0.70, 1.44)	0.964
Lower vs. cervical	1.49 (1.02, 2.17)	0.022	1.27 (0.85, 1.90)	0.240
Radiotherapy technology (IMRT vs. 3DCRT)	0.77 (0.63, 0.95)	0.013	0.84 (0.68, 1.03)	0.092
Treatment options (CCRT vs. SCRT)	1.21 (0.98, 1.47)	0.067	–	–
Dose (>58.8 vs. ≤58.8 Gy)	0.74 (0.59, 0.93)	0.008	0.87 (0.69, 1.90)	0.247
CEA (ng/mL)				
>5.5 vs. ≤5.5	1.28 (1.01, 1.62)	0.041	1.09 (0.86, 1.39)	0.482
NA vs. ≤5.5	1.13 (0.88, 1.44)	0.355	1.16 (0.88, 1.53)	0.307
Cyfra21-1 (ng/mL)				
>6.4 vs. ≤6.4	2.45 (1.73, 3.45)	<0.001	1.90 (1.33, 2.72)	<0.001
NA vs. ≤6.4	1.02 (0.82, 1.26)	0.864	0.98 (0.77, 1.25)	0.870
LDH (>134 vs. ≤134 U/L)	1, 62 (1.14, 2.29)	0.007	1.61 (1.13, 2.30)	0.009

HR, hazard ratio; CI, confidence interval; LDH, lactate dehydrogenase; ECOG, Eastern Clinical Oncology Group; PS, performance status; Cyfra21-1, cytokeratin 19 fragment antigen 21-1; CEA, carcinoembryonic antigen; 3D-CRT, 3-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; CCRT, concurrent chemoradiotherapy; SCRT, sequential chemoradiotherapy; cT stage, clinical T stage; cN stage, clinical N stage; cM stage, clinical M stage; ESCC, esophageal squamous cell carcinoma; PFS, progression-free survival.

Table S2 Univariate and multivariate analysis of OS in patients with ESCC before propensity score matching

Variable	Univariate		Multivariate	
	HR (95% CI)	P value	HR (95% CI)	P value
Gender (female vs. male)	0.71 (0.54, 0.94)	0.016	0.74 (0.56, 0.99)	0.043
Age (>69 vs. ≤69 years)	1.37 (1.06, 1.77)	0.015	1.16 (0.88, 1.55)	0.296
ECOG PS (1–2 vs. 0)	1.47 (1.18, 1.83)	0.001	1.37 (1.06, 1.76)	0.014
cT stage (T3-4 vs. T1-2)	1.13 (0.77, 1.66)	0.522		
cN stage (N+ vs. N0)	2.34 (1.55, 3.55)	<0.001	2.14 (1.40, 3.27)	<0.001
cM stage (M1 vs. M0)	1.67 (1.31, 2.13)	<0.001	1.52 (1.18, 1.97)	0.001
Differentiation (moderate/poor vs. high)	1.00 (0.76, 1.32)	0.999	–	–
Tumor length (>6.5 vs. ≤6.5 cm)	1.45 (1.12, 1.88)	0.005	1.45 (1.11, 1.89)	0.007
Tumor location				
Upper vs. cervical	0.95 (0.63, 1.42)	0.783	0.89 (0.60, 1.34)	0.585
Medium vs. cervical	1.21 (0.83, 1.77)	0.328	0.95 (0.64, 1.41)	0.795
Lower vs. cervical	1.58 (1.04, 2.40)	0.031	1.24 (0.80, 1.91)	0.334
Radiotherapy technology (IMRT vs. 3DCRT)	0.79 (0.64, 0.99)	0.037	0.86 (0.68, 1.08)	0.196
Treatment options (CCRT vs. SCRT)	1.21 (0.98, 1.51)	0.081	–	–
Dose (>58.8 vs. ≤58.8 Gy)	0.72 (0.57, 0.92)	0.008	0.87 (0.67, 1.12)	0.278
CEA (ng/mL)				
>5.5 vs. ≤5.5	1.26 (0.97, 1.63)	0.080	1.06 (0.81, 1.38)	0.693
NA vs. ≤5.5	1.09 (0.83, 1.44)	0.515	1.01 (0.75, 1.38)	0.919
Cyfra21-1 (ng/mL)				
>6.4 vs. ≤6.4	2.45 (1.73, 3.45)	0.000	1.90 (1.33, 2.72)	0.000
NA vs. ≤6.4	1.02 (0.82, 1.26)	0.864	0.98 (0.77, 1.25)	0.870
LDH (>134 vs. ≤134 U/L)	1.64 (1.12, 2.42)	0.012	1.64 (1.10, 2.43)	0.015

HR, hazard ratio; CI, confidence interval; LDH, lactate dehydrogenase; ECOG, Eastern Clinical Oncology Group; PS, performance status; Cyfra21-1, cytokeratin 19 fragment antigen 21-1; CEA, carcinoembryonic antigen; 3D-CRT, 3-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; CCRT, concurrent chemoradiotherapy; SCRT, sequential chemoradiotherapy; cT stage, clinical T stage; cN stage, clinical N stage; cM stage, clinical M stage; ESCC, esophageal squamous cell carcinoma.